Bradley J. Monk
Impact in
- Obstetrics and Gynecology top 0.01%
- Endometrial and Cervical Cancer Treatments
- Reproductive Medicine top 0.01%
- Ovarian cancer diagnosis and treatment
Papers in
-
- Ovarian cancer diagnosis and treatment 250
- Oncology 218
- PARP inhibition in cancer therapy 91
- Cancer Immunotherapy and Biomarkers 50
- Co-authors
- Robert A. Burger (75 shared papers)Krishnansu S. Tewari (89 shared papers)Michael W. Sill (21 shared papers)Helen Huang (24 shared papers)Benjamin E. Greer (10 shared papers)Thomas J. Herzog (61 shared papers)David S. Alberts (16 shared papers)Robert L. Coleman (96 shared papers)
- Journals
- Gynecologic Oncology (189 papers)Journal of Clinical Oncology (131 papers)International Journal of Gynecological Cancer (69 papers)Annals of Oncology (36 papers)American Journal of Obstetrics and Gynecology (11 papers)
- Partner nations
- United StatesSpainItaly
In The Last Decade
Bradley J. Monk
595 papers receiving 23.1k citations
Bradley J. Monk's Hit Papers
Peers
Comparison fields: 5 of 154
- Obstetrics and Gynecology 6.7k
- Reproductive Medicine 6.8k
- Oncology 6.4k
- Cancer Research 1.7k
- Epidemiology 3.2k
Countries citing papers authored by Bradley J. Monk
This map shows the geographic impact of Bradley J. Monk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bradley J. Monk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bradley J. Monk more than expected).
Fields of papers citing papers by Bradley J. Monk
This network shows the impact of papers produced by Bradley J. Monk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bradley J. Monk. The network helps show where Bradley J. Monk may publish in the future.
Co-authors
The 25 scholars most cited alongside Bradley J. Monk, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 619 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix Hit paper breakdown → | 2000 | 1746 |
| 2 | Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer Hit paper breakdown → | 2011 | 1668 |
| 3 | Improved Survival with Bevacizumab in Advanced Cervical Cancer Hit paper breakdown → | 2014 | 1038 |
| 4 | Carcinogenic human papillomavirus infection Hit paper breakdown → | 2016 | 652 |
| 5 | Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study Hit paper breakdown → | 2007 | 647 |
| 6 | Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer Hit paper breakdown → | 2021 | 619 |
| 7 | Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer Hit paper breakdown → | 2001 | 546 |
| 8 | Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study Hit paper breakdown → | 2009 | 501 |
| 9 | Latest research and treatment of advanced-stage epithelial ovarian cancer Hit paper breakdown → | 2013 | 410 |
| 10 | Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial Hit paper breakdown → | 2019 | 390 |
| 11 | 2003 | 308 | |
| 12 | 2010 | 291 | |
| 13 | Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer Hit paper breakdown → | 2016 | 253 |
| 14 | 2009 | 246 | |
| 15 | 1994 | 214 | |
| 16 | 2015 | 204 | |
| 17 | 2010 | 198 | |
| 18 | 2012 | 197 | |
| 19 | Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I Hit paper breakdown → | 2021 | 196 |
| 20 | 2007 | 182 |
About Bradley J. Monk
Bradley J. Monk is a scholar working on Reproductive Medicine, Oncology, Obstetrics and Gynecology, Pulmonary and Respiratory Medicine and Epidemiology, having authored 619 papers that have together received 23.6k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (250 papers), Endometrial and Cervical Cancer Treatments (159 papers), PARP inhibition in cancer therapy (91 papers), Cervical Cancer and HPV Research (64 papers), Cancer Immunotherapy and Biomarkers (50 papers), Cancer Genomics and Diagnostics (37 papers), Lung Cancer Treatments and Mutations (22 papers) and Renal cell carcinoma treatment (21 papers). The work is most often cited by research in Obstetrics and Gynecology (6.7k citations), Reproductive Medicine (6.8k citations), Oncology (6.4k citations), Cancer Research (1.7k citations) and Epidemiology (3.2k citations). Bradley J. Monk has collaborated with scholars based in United States, Spain and Italy. Frequent co-authors include Robert A. Burger, Krishnansu S. Tewari, Michael W. Sill, Helen Huang, Benjamin E. Greer, Thomas J. Herzog, David S. Alberts, Robert L. Coleman, Jonathan S. Berek and Richard J. Stock. Their work appears in journals such as Gynecologic Oncology, Journal of Clinical Oncology, International Journal of Gynecological Cancer, Annals of Oncology and American Journal of Obstetrics and Gynecology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.